<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03289208</url>
  </required_header>
  <id_info>
    <org_study_id>MCI-186-J22</org_study_id>
    <nct_id>NCT03289208</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Mild or Moderate Renal Impairment Compared to Subjects With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the pharmacokinetics of MCI-186 after a single intravenous infusion of 30mg/hour in
      subjects with mild or moderate renal impairment compared to subjects with normal renal
      function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>pre-dose to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-last</measure>
    <time_frame>pre-dose to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>pre-dose to 48 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>t½</measure>
    <time_frame>pre-dose to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Renal Impairment</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>moderated renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCI-186</intervention_name>
    <description>30 mg of edaravone will be administered intravenously over 60 minutes.</description>
    <arm_group_label>mild renal impairment</arm_group_label>
    <arm_group_label>moderated renal impairment</arm_group_label>
    <arm_group_label>normal renal function</arm_group_label>
    <other_name>Edaravone</other_name>
    <other_name>Radicut</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects

          -  Able to provide written informed consent to participate in this study after reading
             the ICF

          -  Subjects is able to understand and willing to cooperate and comply with the Protocol
             restrictions and requirements

          -  A body weight of ≥45 kg in males or ≥40 kg in females and a body mass index ranging
             from 18 to 30 kg/m2

        Renal impaired subjects (in addition)

          -  Subjects with mild renal impairment defined as eGFR 60-89 mL/min/1.73m2 and subjects
             with moderate renal impairment defined as eGFR 30-59 mL/min/1.73m2

          -  Chronic and stable renal impairment

        Healthy subjects (in addition)

          -  Subject with normal renal function defined as eGFR≥90 mL/min/1.73m2

          -  Good health and free from clinically significant illness or disease

        Exclusion Criteria:

        All subjects

          -  Presence or history of severe allergy to food, or any medicinal product or relevant
             excipient that is of clinical significance

          -  Subjects were previously administered MCI-186

          -  Positive urine drug screen (if not due to concomitant medication) or alcohol test

          -  History of alcohol abuse or drug abuse

          -  Presence of active infection requiring antibiotics

          -  Positive test for human immunodeficiency virus (HIV) antigen/antibody, hepatitis B
             surface antigen (HBsAg), or hepatitis C virus antibody (HCVAb)

        Renal impairment subject (in addition)

          -  Acute renal failure

          -  History of renal transplantation

          -  Aspartate aminotransferase (AST) activity, or an alanine aminotransferase (ALT)
             activity of at least 3 times the upper limit of normal (ULN) range

          -  Uncontrolled, or untreated hypertension defined as systolic blood pressure (SBP)&gt;180
             mmHg and/or diastolic blood pressure (DBP)&gt;110 mmHg

          -  Start of any new medication or new any changes to a current dosage

        Healthy subject (in addition)

          -  History or presence of any renal disease

          -  Uncontrolled, or untreated hypertension defined as systolic blood pressure (SBP)&gt;160
             mmHg and/or diastolic blood pressure (DBP)&gt;100 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Information Desk, to prevent miscommunication,</last_name>
    <phone>please email:</phone>
    <email>cti-inq-ml@ml.mt-pharma.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2017</study_first_submitted>
  <study_first_submitted_qc>September 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2017</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylmethylpyrazolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

